CMMB
Chemomab Therapeutics Ltd DRC
NASDAQ: CMMB · HEALTHCARE · BIOTECHNOLOGY
$1.47
+0.68% today
Updated 2026-04-30
Market cap
$11.59M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.44
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
Chemomab Therapeutics Ltd DRC (CMMB) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | — | — | — | $9.48M | — | — | $3.52M | $5.65M | $2.09M | $12.76M | $19.76M | $12.48M | $64.35M | $43.06M | $22.15M | $16.96M |
| Cash & equivalents | — | — | — | — | $5.72M | — | — | $2.21M | $4.56M | $1.45M | $7.52M | $17.58M | $11.67M | $14.69M | $13.52M | $9.29M | $6.07M |
| Current assets | — | — | — | — | $9.16M | — | — | $3.10M | $4.87M | $1.59M | $10.92M | $18.21M | $11.84M | $62.69M | $41.74M | $20.90M | $16.04M |
| Total liabilities | — | — | — | — | $6.19M | — | — | $1.37M | $2.36M | $2.70M | $2.96M | $4.85M | $1.67M | $2.89M | $6.84M | $5.15M | $3.43M |
| Current liabilities | — | — | — | — | $4.89M | — | — | $1.33M | $2.36M | $2.70M | $2.75M | $4.12M | $1.32M | $2.65M | $6.75M | $4.84M | $3.22M |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Shareholder equity | — | — | — | — | $3.29M | — | — | $2.14M | $3.29M | $-609000.00 | $9.80M | $12.37M | $10.80M | $61.47M | $36.22M | $17.00M | $13.54M |
| Retained earnings | — | — | — | — | $-112.75M | — | — | $-47.46M | $-52.70M | $-62.88M | $-78.31M | $-17.74M | $-23.70M | $-36.17M | $-63.82M | $-88.68M | $-102.62M |
| Accounts receivable | — | — | — | — | $192170.00 | — | — | $129785.00 | $139009.00 | $88000.00 | $3.40M | $636000.00 | $74000.00 | $179000.00 | $459000.00 | $289000.00 | $263000.00 |
| Inventory | — | — | — | — | — | — | — | — | $1.00 | — | $-77000.00 | $-542.00 | $-657000.00 | $-1.35M | — | $-1.04M | $1.00 |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |